Friday, May 1, 2020
- 2:30PM-3:00PM
-
Abstract Number: 006
Increasing Rates of Standardized Depression Screening in Youth with Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
Plenary Abstracts Session 2- 2:30PM-3:00PM
-
Abstract Number: 005
Single Cell Sequencing of the Skin to Define Cell Populations of Interest in Localized Scleroderma (LS)
Plenary Abstracts Session 2- 4:30PM-5:00PM
-
Abstract Number: 028
A Randomized, Double-blind, Placebo-controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease
Poster Breakout 4 – Updates on Therapeutics- 4:30PM-5:00PM
-
Abstract Number: 026
Allogeneic Hematopoietic Cell Transplantation (HCT) in the National Institutes of Health (NIH)’s Deficiency of Adenosine Deaminase 2 (DADA2) Patient Cohort
Poster Breakout 4 – Updates on Therapeutics- 4:30PM-5:00PM
-
Abstract Number: 039
Assessing Patient Self-Reported Transition Readiness in a Large Pediatric Rheumatology Center
Poster Breakout 6 – Patient Experience & Care Optimization- 4:30PM-5:00PM
-
Abstract Number: 038
Change in Treatments and Outcomes After Implementation of a National Diagnosis and Treatment Guarantee Program for Juvenile Idiopathic Arthritis in Chile
Poster Breakout 6 – Patient Experience & Care Optimization- 4:30PM-5:00PM
-
Abstract Number: 034
Chest Computed Tomography Manifestations in Childhood-Onset Systemic Lupus Erythematosus: A Single-Center Cohort Study
Poster Breakout 5 – Systemic Lupus Erythematosus- 4:30PM-5:00PM
-
Abstract Number: 027
Clinical Features and Outcomes in Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE) Syndrome: Before and After JAK-inhibition
Poster Breakout 4 – Updates on Therapeutics- 4:30PM-5:00PM
-
Abstract Number: 029
Comparison of Efficacy Between Triamcinolone Acetonide and Hexacetonide Intra-articular Treatment for Clinical Remission in Juvenile Idiopathic Arthritis
Poster Breakout 4 – Updates on Therapeutics- 4:30PM-5:00PM
-
Abstract Number: 031
Exome Sequencing for Early Pediatric Systemic Lupus Erythematosus: Standard of Care in 2020?
Poster Breakout 5 – Systemic Lupus Erythematosus- 4:30PM-5:00PM
-
Abstract Number: 037
Improving Pneumococcal Vaccination Rates in Immunosuppressed Rheumatology Patients
Poster Breakout 6 – Patient Experience & Care Optimization- 4:30PM-5:00PM
-
Abstract Number: 036
Medication Related Decision-Making in Parents of Children with Juvenile Idiopathic Arthritis
Poster Breakout 6 – Patient Experience & Care Optimization- 4:30PM-5:00PM
-
Abstract Number: 033
Parental Adverse Childhood Experience (ACE) Exposure Is Predictive of Active Lupus in Pediatric Patients